By Annalee Armstrong, Gabrielle Masson, James Waldron, Max Bayer, Ben Adams – Fierce Biotech
We’re off for another day of the J.P. Morgan Healthcare Conference 2024. The flood of licensing deals and M&A may have slowed, but there’s still plenty of action to come as companies make pitches to their peers, investors and industry watchers.
We start off the day with a recap of the gene editors.
Our Day 1 conference tracker is available here, and all the Day 2 action is wrapped here. Fierce Pharma’s take on the action so far can be found here and here.